This panel explores early-stage biotech syndication between CVCs and seed investors. It covers roles, alignment, and evolving market dynamics, including selectivity and collaboration. Discussion highlights incentives, ticket sizes, and engagement, plus how strong syndicates are built and led. Panelists examine value inflection points, risk-sharing, and valuation trends. Differences between US and Europe are considered, alongside future funding roles. Challenges to syndicate financing rounds at early stage will be discussed. Moderators use prompts to deepen insight and reveal challenges, trade-offs, and practical lessons for founders.
Tuesday, May 5, 12:15 - 13:00, room Kairo
| Name | Position | Institution |
|---|---|---|
| Claudia Ulbrich, MD | Venture Partner | BiomedVC AG |
| Name | Position | Institution |
|---|---|---|
| Valentin Piech, PhD | Managing Partner | BiomedVC AG |
| Jan-Philipp Kruse, PhD | Senior Director | Lilly Ventures |
| Roger Franklin, PhD | Partner | HADEANVENTURES |
| Naveed Siddiqi, MD | Senior Partner | Novo Holdings A/S |
| Mathias Frederiksen, PhD | Principal | Novartis Venture Fund |
BiomedVC was founded in 2021 to continue the legacy of BioMedPartners by empowering the next generation of Life Science entrepreneurs to take their scientific innovation from academic labs and build them into venture-backed biotechs developing innovative therapeutics for high-unmet medical needs.
We support first-time teams or experienced founders with initial investments in Seed and Series A stages and our experience and dedication as partners on a basis of equality. We lead and co-lead investment rounds and keep reserves for future rounds. We invest in continental Europe with a focus on the DACH region, in particular Switzerland and Germany
